Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors

被引:37
作者
Elting, LS
Cantor, SB
Martin, CG
Hamblin, L
Kurtin, D
Rivera, E
Vadhan-Raj, S
Benjamin, RS
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Sect Hlth Serv Res, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Gen Internal Med, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[4] Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA
关键词
thrombocytopenia; cost of care; cost of illness; incremental costs; complications of chemotherapy; platelet transfusions;
D O I
10.1002/cncr.11195
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The purpose of this study was to estimate the mean incremental cost of chemotherapy-induced thrombocytopenia and the drivers of cost. Another goal was to estimate the impact of depth and duration of thrombocytopenia on the cost of thrombocytopenia. METHODS. A retrospective cohort, consisting of a random sample of 75 solid tumor or lymphoma patients who developed chemotherapy-induced thrombocytopenia (less than or equal to50,000 platelets per mul), was chosen. The number of each type of resource used during 217 cycles with and 300 cycles without thrombocytopenia were multiplied by the cost of each resource and summed to yield the total cost of care (in 1999 dollars from the provider's perspective). RESULTS. Compared with cycles without thrombocytopenia, the mean incremental cost of thrombocytopenia was $1037 per cycle. However, 60% of cycles were usual cost, with a mean cost of thrombocytopenia of $43 per cycle less than control cycles. Twelve percent of cycles were high cost (mean incremental cost = $612 per cycle); 28% were very high cost (mean incremental cost = $3519). The excess cost during high-cost cycles was due to high consumption of prophylactic platelet transfusions and during very high-cost cycles to both higher platelet transfusion consumption and to a high incidence of major bleeding episodes. CONCLUSIONS. Although thrombocytopenia is a common complication of chemotherapy, only 40% of cycles with thrombocytopenia would be considered high or very high cost. Interventions targeted at this subset of cycles could significantly reduce the cost of thrombocytopenia provided they are initiated early enough in the chemotherapy experience to be effective. (C) 2003 American Cancer Society.
引用
收藏
页码:1541 / 1550
页数:10
相关论文
共 44 条
[1]   Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double-blind trial [J].
Ackerman, SJ ;
Klumpp, TR ;
Guzman, GI ;
Herman, JH ;
Gaughan, JP ;
Bleecker, GC ;
Mangan, KF .
TRANSFUSION, 2000, 40 (12) :1457-1462
[2]   CONTROVERSIES IN TRANSFUSION MEDICINE - PROPHYLACTIC PLATELET TRANSFUSION THERAPY - PRO [J].
BAER, MR ;
BLOOMFIELD, CD .
TRANSFUSION, 1992, 32 (04) :377-380
[3]   COST-EFFECTIVENESS OF WHITE CELL-REDUCTION FILTERS IN TREATMENT OF ADULT ACUTE MYELOGENOUS LEUKEMIA [J].
BALDUCCI, L ;
BENSON, K ;
LYMAN, GH ;
SANDERSON, R ;
FIELDS, K ;
BALLESTER, OF ;
ELFENBEIN, GJ .
TRANSFUSION, 1993, 33 (08) :665-670
[4]  
BASSER R, 1999, ASCO ED BOOK SPR, P266
[5]   INCIDENCE OF HEMORRHAGIC COMPLICATIONS IN PATIENTS WITH CANCER [J].
BELT, RJ ;
LEITE, C ;
HAAS, CD ;
STEPHENS, RL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1978, 239 (24) :2571-2574
[6]   A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation [J].
Bernstein, SH ;
Nademanee, AP ;
Vose, JM ;
Tricot, G ;
Fay, JW ;
Negrin, RS ;
DiPersio, J ;
Rondon, G ;
Champlin, R ;
Barnett, MJ ;
Cornetta, K ;
Herzig, GP ;
Vaughan, W ;
Geils, G ;
Keating, J ;
Messner, H ;
Wolff, SN ;
Miller, KB ;
Linker, C ;
Cairo, M ;
Hellmann, S ;
Ashby, M ;
Stryker, S ;
Nash, RA .
BLOOD, 1998, 91 (09) :3509-3517
[7]  
BEUTLER E, 1993, BLOOD, V81, P1411
[8]   ICONOCLASTIC VIEW OF CONVENTIONAL WISDOMS IN HEMATOLOGY [J].
BEUTLER, E .
ARCHIVES OF INTERNAL MEDICINE, 1979, 139 (02) :221-223
[9]   Evaluating the total costs of chemotherapy-induced toxicity: Results from a pilot study with ovarian cancer patients [J].
Calhoun, EA ;
Chang, CH ;
Welshman, EE ;
Fishman, DA ;
Lurain, JR ;
Bennett, CL .
ONCOLOGIST, 2001, 6 (05) :441-445
[10]  
DUTCHER JP, 1984, CANCER, V53, P557, DOI 10.1002/1097-0142(19840201)53:3<557::AID-CNCR2820530331>3.0.CO